Bio-Techne Corporation Reports Strong Q2 Fiscal 2025 Financial Results with Notable Organic Growth

Bio-Techne Corporation Reports Strong Q2 Fiscal 2025 Financial Results

On February 5, 2025, Bio-Techne Corporation (NASDAQ: TECH) published its financial results for the second quarter ending December 31, 2024. The report showcased impressive advancements, highlighting an organic revenue increase of 9%, totaling $297.0 million.

Key Highlights from Q2 FY2025

The company's earnings per share (EPS) under Generally Accepted Accounting Principles (GAAP) was reported at $0.22, a rise from $0.17 in the previous year. Adjusted EPS also saw growth, reaching $0.42 compared to $0.40 from the previous year. This robust performance can be attributed to improving market conditions within the biopharma sector, along with sustained progress in cell and gene therapy workflow solutions. Notably, the Protein Sciences Segment achieved an organic growth rate of 8% and the Diagnostics and Spatial Biology Segment reported a remarkable 12% organic growth.

Kim Kelderman, President and CEO of Bio-Techne, expressed satisfaction with the results, stating, "The Bio-Techne team once again executed at a high level and delivered strong second quarter results. It's encouraging to witness early signs of recovery in the biopharma end-market, particularly in our cell and gene therapy and protein analysis instrumentation businesses."

Detailed Financial Performance

In terms of net sales within the Protein Sciences Segment, there was an increase to $211.6 million, marking a 7% rise from $197.7 million for the same quarter the previous year. Despite the growth, the sales were slightly impacted by a business that was held-for-sale, reducing the overall sales by 1%. The segment also reported an operating margin improvement, climbing to 41.2%, compared to 40.3% during the same period last year.

On the other hand, the Diagnostics and Spatial Biology Segment saw its sales rise to $84.1 million, an increase of 12% from $75.4 million in Q2 of fiscal 2024. However, the segment's operating margin experienced a decline to 3.9% from the previous year's 6.0%, primarily due to reinstated incentive compensation accruals.

Future Outlook

Bio-Techne remains committed to capitalizing on its unique portfolio, which is pivotal for the discovery of biological insights, the development of advanced therapeutics, and the enhancement of precision diagnostics. The management team believes their strong market position will sustain differentiated financial performance moving forward.

In conclusion, Bio-Techne's second-quarter results for fiscal 2025 reflect an impressive trajectory of growth and resilience, positioning the company favorably for sustained advancement in the future. The full transcript of the earnings conference call offers additional insights into the company’s strategic directions and growth initiatives.

Additional Information

The company will host a earnings conference call today at 8:00 a.m. CST, available to the public via webcast. A recorded replay will also be accessible for those unable to attend the live call. For further queries or details regarding Bio-Techne’s performance, stakeholders can refer to the investor relations section on their website.